J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gavras, H
Right arrow Articles by Laragh, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gavras, H
Right arrow Articles by Laragh, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Effect of a new beta-adrenergic blocker, l-bunolol, on blood pressure and on the renin-aldosterone system

H Gavras, I Gavras, HR Brunner, and JH Laragh

The antihypertensive effect of a new beta-adrenergic receptor blocker, l-bunolol, was evaluated in 11 hospitalized hypertensive patients of whom four belonged to the high-renin, five to the normal-renin, and two to the low-renin subgroup. There was a significant decrease in blood pressure in most patients, often to normal. Moreover, plasma renin levels were nearly always markedly suppressed, and this suppression preceded the fall in blood pressure. While most high and normal renin patients responded, the numbers of patients within each subgroup were too small to correlate the blood pressure responses with changes in renin levels. There was a significant induced decrease in aldosterone excretion, which usually paralleled the renin suppression. Pulse rate was also consistently reduced during treatment. No weight gain was observed, except in one patient who developed overt congestive cardiac failure. No other side effects were recorded. Ii is concluded that l-bunolol is another beta-blocking drug with significant antihypertensive action. It was found to be effective in cases that were resistant to propranolo. It is well tolerated and safe to use, provided that early evidence of fluid retention is sought for and treated immediately.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1977 by the American College of Clinical Pharmacology